Live Quote · WSECTX.WAHealthcare· Medical - Pharmaceuticals

Captor Therapeutics Spolka Akcyjna

$76.10 0.91%($-0.70)
TickerSpark Score
41/100
Weak
20
Valuation
20
Profitability
35
Growth
68
Health
60
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTX.WA research report →

52-Week Range77% of range
Low
$31.50
Current
$76.10
High
$89.20

About the company

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the blood, lymphatic system, and bone marrow; and CT-01, which also completed the Phase 1 clinical trials for the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor.

CEO
Michal Jerzy Walczak
IPO
2021
Employees
91
HQ
Wroclaw, SL, PL

Price Chart

+129.22% · this period
$87.60$59.75$31.90Jun 20Dec 17Jun 24
Valuation
Market Cap
$481.97M
P/E
-9.86
P/S
202.34
P/B
35.02
EV/EBITDA
-11.87
Div Yield
0.00%
Profitability
Gross Margin
3.44%
Op Margin
-1973.80%
Net Margin
-1790.64%
ROE
-150.18%
ROIC
-306.09%
Growth & Income
Revenue
$4.66M · -70.55%
Net Income
$-41,997,000 · -9.29%
EPS
$-7.61 · 7.76%
Op Income
$-53,207,000
FCF YoY
-13.93%
Performance & Tape
52W High
$89.20
52W Low
$31.50
50D MA
$78.52
200D MA
$67.51
Beta
0.65
Avg Volume
3.36K

Get TickerSpark's AI analysis on CTX.WA

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Coverage · CTX.WA

Our CTX.WA coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on CTX.WA yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate CTX.WA report →
Internal Compare

Similar companies

Peers in the same neighborhood.